Risk-reducing strategies #2
In premenopausal women with breast cancer with a confirmed germline mutation (e.g. BRCA 1/2) that predisposes to an increased risk of breast cancer, discuss risk-reducing strategies (e.g. contralateral risk-reducing mastectomy or endocrine therapy/ risk-reducing medication).
Surgical risk-reducing strategies in women diagnosed with breast cancer with a BRCA1/2 mutation. Discuss contralateral risk reducing mastectomy with women diagnosed with breast cancer with a BRCA1/2 mutation, particularly in younger women (less than 50 years), to substantially decrease the risk of contralateral breast cancer
Body of evidence can be trusted to guide practice in most situations
How this guidance was developed
This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'B' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by removing the specification of BRCA1/2 mutations, specification of gender in the patient population, and the focus on young women and contralateral risk-reducing strategies.
Risk-reducing strategies #2
In premenopausal women with breast cancer with a confirmed germline mutation (e.g. BRCA 1/2) that predisposes to an increased risk of breast cancer, discuss risk-reducing strategies (e.g. contralateral risk-reducing mastectomy or endocrine therapy/ risk-reducing medication).
This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'B' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by removing the specification of BRCA1/2 mutations, specification of gender in the patient population, and the focus on young women and contralateral risk-reducing strategies.